<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00652314</url>
  </required_header>
  <id_info>
    <org_study_id>0307</org_study_id>
    <secondary_id>The CONTROL Study</secondary_id>
    <nct_id>NCT00652314</nct_id>
  </id_info>
  <brief_title>Evaluation of an Absorbable Surgical Hemostatic Agent: Thrombi-Gel® Versus Gelfoam-Thrombin</brief_title>
  <acronym>Control</acronym>
  <official_title>Evaluation of an Absorbable Surgical Hemostatic Agent: Thrombi-Gel® Versus Gelfoam-Thrombin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vascular Solutions, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>King Pharmaceuticals is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Vascular Solutions, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is designed as a prospective, multi-center, randomized, feasibility clinical trial
      to evaluate the safety and efficacy of Thrombi-Gel as an absorbable surgical hemostat.

      Within this clinical evaluation, Thrombi-Gel will be compared to the current standard of
      care, a gelatin sponge (Gelfoam) plus Thrombin JMI, by using a 2:1 randomization ratio.
      Subjects will be randomized to one of two (2) treatment groups. One (1) group will be treated
      with Thrombi-Gel, while one (1) group will be treated with the gelatin sponge plus thrombin.
      All study data will be analyzed according to the subjects' assigned randomization group
      assignment, regardless of the treatment actually delivered.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, randomized, multi-center investigation with a minimum of seventy five
      (75) study subjects designed to evaluate the safety and effectiveness of the Thrombi-Gel
      product as an absorbable hemostat in the surgical patient population.

      Subjects who are undergoing orthopedic/spinal, general, cardiac, hepatic or vascular surgical
      procedures should be considered for this investigation. Subjects can be pre-screened
      utilizing standard of care data for the specified inclusion/exclusion criteria to ensure that
      they are eligible for treatment in the investigation. If the subject appears to qualify for
      the investigation, the subject will then be asked to give his/her written informed consent.
      If, during surgery, the surgeon encounters a bleeding site that he or she is unable or
      unwilling to easily control due to failure or impracticality of conventional methods (sutures
      and/or cautery), the subject may be enrolled and randomized to receive either the
      investigational or control treatment. If the subject has multiple bleeding sites, each site
      to a maximum of 5 sites, may be treated with the assigned surgical hemostat. However, only
      the first site treated will be used to determine study objectives. All subjects will be
      followed through their hospitalization.

      A follow-up evaluation will be conducted at approximately 30 and 60 days post-procedure to
      determine the long-term effectiveness of the hemostatic treatment received, incidence of late
      adverse events, and interim immunologic response to the study treatment device. Follow-up
      evaluations will include obtaining a blood specimen that evaluates for antibody development,
      coagulation, and Factor Va testing. Blood samples will be sent to independent labs for
      analysis.

      From baseline to the final study exam, data pertaining to the investigational objectives will
      be recorded on the appropriate case report forms at the predetermined study intervals. The
      investigation will be conducted at a minimum of five (5) sites, but no more than fifteen (15)
      sites.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Primary Objective of This Investigation is to Gather Information to Support the Effectiveness of Thrombi-Gel as Compared to a Gelatin Sponge (Gelfoam) Plus Thrombin as an Adjunct to Hemostasis in Multi-specialty Surgical Settings.</measure>
    <time_frame>Time to hemostasis (minutes)</time_frame>
    <description>Evaluation for hemostasis began immediately following application of the safety product. Hemostasis assessments were to be made every minute for the first 10 minutes post application. If hemostasis was not observed within 10 minutes, the treatment site was to be monitored and the research teams were asked to record the specific number of minutes until hemostasis was observed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effectiveness: Device Success (Defined as the Number of Subjects With First Bleeding Site Applications for Which Hemostasis Was Obtained Within 6 Minutes of Study Device Application Without the Need for Adjunctive Treatment)</measure>
    <time_frame>Procedure, up to 6 minutes post procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effectiveness: Hemostatic Handling Characteristics (Surgeon's Questionnaire)</measure>
    <time_frame>Procedure (application through end of procedure)</time_frame>
    <description>Ease of application to bleeding site as assessed by surgeon questionnaire for hemostatic handling characteristics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Incidence Rate of Device-related Adverse Events</measure>
    <time_frame>Procedure, up to 60 days post procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Immunological Testing for Factor Va Antibodies and Coagulation Parameters</measure>
    <time_frame>0 day, 30 day, and 60 days post procedure</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">97</enrollment>
  <condition>Operation Site Bleed</condition>
  <arm_group>
    <arm_group_label>1 - Thrombi-gel treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Thrombi-gel treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 - Gelatin Sponge (Gelfoam)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gelatin Sponge (Gelfoam) plus thrombin</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Thrombi-Gel</intervention_name>
    <description>Applicaton of Hemostatic product during surgery</description>
    <arm_group_label>1 - Thrombi-gel treatment</arm_group_label>
    <arm_group_label>2 - Gelatin Sponge (Gelfoam)</arm_group_label>
    <other_name>Gelatin Sponge (Gelfoam) plus thrombin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The subject is 18 years of age or older

          2. The subject is undergoing an orthopedic/spinal, general, cardiac, hepatic, or vascular
             surgical procedure (neurosurgical, ophthalmic or urological procedures must be
             excluded)

          3. The subject is willing and able to provide appropriate informed consent

          4. The subject is willing and able to comply with the requirements of the study protocol,
             including the predefined follow-up evaluations

        Inclusion criteria to be determined during the surgical procedure:

        1. The subject has an intraoperative bleeding site which the surgeon is unable or unwilling
        to easily control with conventional methods (cautery, sutures)

        Exclusion Criteria:

          1. The subject is known or suspected to be pregnant (verified in a manner consistent with
             institution's standard of care), or is lactating

          2. The subject has a known allergy to bovine derived products or any other materials used
             in the Thrombi-Gel product

          3. The subject has an active infection at the surgical site

          4. The use of hemostatic agents are contraindicated for the subject

          5. The subject has a known bleeding disorder (including thrombocytopenia [&lt; 100,000
             platelet count], thrombobasthenia, hemophilia, or von Willebrand disease)

          6. The subject has received antibiotic solutions/powders at the intended application site

          7. The subject has had surgery at the intended application site ≤ 6 months before the
             current surgical procedure

          8. The subject is unavailable for follow-up

          9. The subject is currently participating in another investigational device or drug trial

         10. The subject has previously participated in this trial (Protocol 0307) or the
             Thrombi-Paste trial (Protocol 0507)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Dolan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lahey Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Southern Illinois University School of Medicine</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>66702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lahey Clinic</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan Vascular Research Center</name>
      <address>
        <city>Flint</city>
        <state>Michigan</state>
        <zip>48507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanford Clinic</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwest Regional Clinical Research</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79412</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Tech University Health Sciences Center</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79415</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 28, 2008</study_first_submitted>
  <study_first_submitted_qc>March 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2008</study_first_posted>
  <results_first_submitted>December 4, 2015</results_first_submitted>
  <results_first_submitted_qc>February 5, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 7, 2016</results_first_posted>
  <last_update_submitted>February 5, 2016</last_update_submitted>
  <last_update_submitted_qc>February 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hemostatic products</keyword>
  <keyword>Surgical hemostasis</keyword>
  <keyword>Thrombi-gel</keyword>
  <keyword>Gelatin Sponge</keyword>
  <keyword>Time to hemostasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemostatics</mesh_term>
    <mesh_term>Thrombin</mesh_term>
    <mesh_term>Gelatin Sponge, Absorbable</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>1 - Thrombi-gel Treatment</title>
          <description>Thrombi-gel treatment
Thrombi-Gel: Applicaton of Hemostatic product during surgery</description>
        </group>
        <group group_id="P2">
          <title>2 - Gelatin Sponge (Gelfoam) Plus Thrombin</title>
          <description>Gelatin Sponge (Gelfoam) plus thrombin
Thrombi-Gel: Applicaton of Hemostatic product during surgery</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>1 - Thrombi-gel Treatment</title>
          <description>Thrombi-gel treatment
Thrombi-Gel: Applicaton of Hemostatic product during surgery</description>
        </group>
        <group group_id="B2">
          <title>2 - Gelatin Sponge (Gelfoam) Plus Thrombin</title>
          <description>Gelatin Sponge (Gelfoam) plus thrombin
Thrombi-Gel: Applicaton of Hemostatic product during surgery</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="62"/>
            <count group_id="B2" value="35"/>
            <count group_id="B3" value="97"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&gt;= to 18 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Primary Objective of This Investigation is to Gather Information to Support the Effectiveness of Thrombi-Gel as Compared to a Gelatin Sponge (Gelfoam) Plus Thrombin as an Adjunct to Hemostasis in Multi-specialty Surgical Settings.</title>
        <description>Evaluation for hemostasis began immediately following application of the safety product. Hemostasis assessments were to be made every minute for the first 10 minutes post application. If hemostasis was not observed within 10 minutes, the treatment site was to be monitored and the research teams were asked to record the specific number of minutes until hemostasis was observed.</description>
        <time_frame>Time to hemostasis (minutes)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1 - Thrombi-gel Treatment</title>
            <description>Thrombi-gel treatment
Thrombi-Gel: Applicaton of Hemostatic product during surgery</description>
          </group>
          <group group_id="O2">
            <title>2 - Gelatin Sponge (Gelfoam) Plus Thrombin</title>
            <description>Gelatin Sponge (Gelfoam) plus thrombin
Thrombi-Gel: Applicaton of Hemostatic product during surgery</description>
          </group>
        </group_list>
        <measure>
          <title>The Primary Objective of This Investigation is to Gather Information to Support the Effectiveness of Thrombi-Gel as Compared to a Gelatin Sponge (Gelfoam) Plus Thrombin as an Adjunct to Hemostasis in Multi-specialty Surgical Settings.</title>
          <description>Evaluation for hemostasis began immediately following application of the safety product. Hemostasis assessments were to be made every minute for the first 10 minutes post application. If hemostasis was not observed within 10 minutes, the treatment site was to be monitored and the research teams were asked to record the specific number of minutes until hemostasis was observed.</description>
          <units>Time to hemostasis (minutes)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.01" spread="4.15"/>
                    <measurement group_id="O2" value="3.72" spread="4.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effectiveness: Device Success (Defined as the Number of Subjects With First Bleeding Site Applications for Which Hemostasis Was Obtained Within 6 Minutes of Study Device Application Without the Need for Adjunctive Treatment)</title>
        <time_frame>Procedure, up to 6 minutes post procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1 - Thrombi-gel Treatment</title>
            <description>Thrombi-gel treatment
Thrombi-Gel: Applicaton of Hemostatic product during surgery</description>
          </group>
          <group group_id="O2">
            <title>2 - Gelatin Sponge (Gelfoam) Plus Thrombin</title>
            <description>Gelatin Sponge (Gelfoam) plus thrombin
Thrombi-Gel: Applicaton of Hemostatic product during surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Effectiveness: Device Success (Defined as the Number of Subjects With First Bleeding Site Applications for Which Hemostasis Was Obtained Within 6 Minutes of Study Device Application Without the Need for Adjunctive Treatment)</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effectiveness: Hemostatic Handling Characteristics (Surgeon’s Questionnaire)</title>
        <description>Ease of application to bleeding site as assessed by surgeon questionnaire for hemostatic handling characteristics.</description>
        <time_frame>Procedure (application through end of procedure)</time_frame>
        <population>Note that the number of participants analyzed (62 and 33) applies to each set of five rows below which apply to the following categories: Ease of application to bleeding site, conformance to tissue surfaces, ease of delivery to hard to reach surfaces, and ease of preparation for use.</population>
        <group_list>
          <group group_id="O1">
            <title>1 - Thrombi-gel Treatment</title>
            <description>Thrombi-gel treatment
Thrombi-Gel: Applicaton of Hemostatic product during surgery</description>
          </group>
          <group group_id="O2">
            <title>2 - Gelatin Sponge (Gelfoam) Plus Thrombin</title>
            <description>Gelatin Sponge (Gelfoam) plus thrombin
Thrombi-Gel: Applicaton of Hemostatic product during surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Effectiveness: Hemostatic Handling Characteristics (Surgeon’s Questionnaire)</title>
          <description>Ease of application to bleeding site as assessed by surgeon questionnaire for hemostatic handling characteristics.</description>
          <population>Note that the number of participants analyzed (62 and 33) applies to each set of five rows below which apply to the following categories: Ease of application to bleeding site, conformance to tissue surfaces, ease of delivery to hard to reach surfaces, and ease of preparation for use.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ease of application to bleeding site - 1 (easy)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ease of application to bleeding site - 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ease of application to bleeding site - 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ease of application to bleeding site - 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ease of application to bleeding site - 5 (hard)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Conformance to tissue surfaces - 1 (well)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Conformance to tissue surfaces - 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Conformance to tissue surfaces - 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Conformance to tissue surfaces - 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Conformance to tissue surfaces - 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ease of delivery to hard to reach surfaces-1(easy)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ease of delivery to hard to reach surfaces - 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ease of delivery to hard to reach surfaces - 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ease of delivery to hard to reach surfaces - 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ease of delivery to hard to reach surfaces-5(hard)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ease of preparation for use - 1 (easy)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ease of preparation for use - 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ease of preparation for use - 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ease of preparation for use - 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ease of preparation for use - 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety: Incidence Rate of Device-related Adverse Events</title>
        <time_frame>Procedure, up to 60 days post procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1 - Thrombi-gel Treatment</title>
            <description>Thrombi-gel treatment
Thrombi-Gel: Applicaton of Hemostatic product during surgery</description>
          </group>
          <group group_id="O2">
            <title>2 - Gelatin Sponge (Gelfoam) Plus Thrombin</title>
            <description>Gelatin Sponge (Gelfoam) plus thrombin
Thrombi-Gel: Applicaton of Hemostatic product during surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Safety: Incidence Rate of Device-related Adverse Events</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serious</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Serious</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety: Immunological Testing for Factor Va Antibodies and Coagulation Parameters</title>
        <time_frame>0 day, 30 day, and 60 days post procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1 - Thrombi-gel Treatment</title>
            <description>Thrombi-gel treatment
Thrombi-Gel: Applicaton of Hemostatic product during surgery</description>
          </group>
          <group group_id="O2">
            <title>2 - Gelatin Sponge (Gelfoam) Plus Thrombin</title>
            <description>Gelatin Sponge (Gelfoam) plus thrombin
Thrombi-Gel: Applicaton of Hemostatic product during surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Safety: Immunological Testing for Factor Va Antibodies and Coagulation Parameters</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bovine FV/Va (0 Day)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bovine FV/Va (30 Day)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bovine FV/Va (60 Day)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bovine Thrombin (0 Day)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bovine Thrombin (30 Day)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bovine Thrombin (60 Day)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Human FV/Va (0 Day)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Human FV/Va (30 Day)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Human FV/Va (60 Day)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Human Thrombin (0 Day)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Human Thrombin (30 Day)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Human Thrombin (60 Day)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>60-Day</time_frame>
      <desc>Adverse events reviewed by an independent clinical events committee (CEC).</desc>
      <group_list>
        <group group_id="E1">
          <title>1 - Thrombi-gel Treatment</title>
          <description>Thrombi-gel treatment
Thrombi-Gel: Applicaton of Hemostatic product during surgery</description>
        </group>
        <group group_id="E2">
          <title>2 - Gelatin Sponge (Gelfoam) Plus Thrombin</title>
          <description>Gelatin Sponge (Gelfoam) plus thrombin
Thrombi-Gel: Applicaton of Hemostatic product during surgery</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal Thrombosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="62"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection/Abscess</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="68" subjects_affected="32" subjects_at_risk="62"/>
                <counts group_id="E2" events="56" subjects_affected="22" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Foreign Body / Hypersensitivity Reaction / Allergic Reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection/Abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Tissue Necrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Lisa Gallatin, RAC</name_or_title>
      <organization>Vascular Solutions, Inc.</organization>
      <phone>763-656-4399</phone>
      <email>lgallatin@vasc.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

